Evidence map›Paper›PMID 34444716›Full record

Observational studyNutrients2021

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics.

María Dolores Arenas Jimenez, Emilio González-Parra, Marta Riera, Abraham Rincón Bello, Ana López-Herradón, Higini Cao, Sara Hurtado, Silvia Collado, Laura Ribera, Francesc Barbosa and 11 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Post-COVID-19 inflammation and sarcopenia in obese diabetic dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

María Dolores Arenas JimenezDepartment of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute, RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain.
Emilio González-ParraFundación Jimenez Díaz, 28040 Madrid, Spain.ORCID 0000-0002-0701-3969
Marta RieraDepartment of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute, RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain.ORCID 0000-0003-4362-7965
Abraham Rincón BelloFresenius Medical Care, Dirección Médica FMC, 28760 Madrid, Spain.
Ana López-HerradónFresenius Medical Care, Dirección Médica FMC, 28760 Madrid, Spain.
Higini CaoDepartment of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute, RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain.
Sara HurtadoFresenius Medical Care, Dirección Médica FMC, 28760 Madrid, Spain.
Silvia ColladoDepartment of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute, RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain.
Laura RiberaFresenius Medical Care, Dirección Médica FMC, 28760 Madrid, Spain.
Francesc BarbosaDepartment of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute, RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain.
Fabiola DapenaDepartment of Nephrology, Consorci Sanitari Alt Penedes Garraf, 08800 Barcelona, Spain.
Vicent TorregrosaDepartment of Nephrology and Kidney Transplantation, Hospital Clinic, 08036 Barcelona, Spain.
José-Jesús BrosetaDepartment of Nephrology, Consorci Sanitari Alt Penedes Garraf, 08800 Barcelona, Spain.ORCID 0000-0002-4559-9083
Carlos Soto MontañezDepartment of Nephrology and Kidney Transplantation, Hospital Clinic, 08036 Barcelona, Spain.
Juan F Navarro-GonzálezResearch Division and Department of Nephrology, Hospital Nuestra Señora de la Candelaria, 38010 Santa Cruz de Tenerife, Spain.ORCID 0000-0002-5015-7474
Rosa RamosFresenius Medical Care, Dirección Médica FMC, 28760 Madrid, Spain.
Jordi BoverDepartment of Nephrology, Hospital Can Ruti, 08916 Barcelona, Spain.
Xavier Nogués-SolanDepartment of Internal Medicine, Hospital del Mar, Institut Mar for Medical Research, CIBERFES, 08003 Barcelona, Spain.
Marta CrespoDepartment of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute, RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain.ORCID 0000-0002-1852-2259
Adriana S DussoBone and Mineral Research Unit, Instituto de Investigaciones Sanitarias del Principado de Asturias, 33011 Oviedo, Spain.
Julio PascualDepartment of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute, RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain.
Hospital Del Mar · ESConsorci Sanitari Garraf · ESHospital Clínic de Barcelona · ESCentro de Investigación Biomédica en Red · ESHospital Universitario Fundación Jiménez Díaz · ESUniversidad de La Laguna · ESWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn COVID-19 patients, low serum vitamin D (VD) levels have been associated with severe acute respiratory failure and poor prognosis. In regular hemodialysis (HD) patients, there is VD deficiency and markedly reduced calcitriol levels, which may predispose them to worse outcomes of COVID-19 infection. Some hemodialysis patients receive treatment with drugs for secondary hyperparathyroidism, which have well known pleiotropic effects beyond mineral metabolism. The aim of this study was to evaluate the impact of VD status and the administration of active vitamin D medications, used to treat secondary hyperparathyroidism, on survival in a cohort of COVID-19 positive HD patients.

methodsA cross-sectional retrospective observational study was conducted from 12 March to 21 May 2020 in 288 HD patients with positive PCR for SARS-CoV2. Patients were from 52 different centers in Spain.

resultsThe percent of HD patients with COVID-19 was 6.1% (288 out of 4743). Mortality rate was 28.4% (81/285). Three patients were lost to follow-up. Serum 25(OH)D (calcidiol) level was 17.1 [10.6-27.5] ng/mL and was not significantly associated to mortality (OR 0.99 (0.97-1.01),

conclusionsOur findings suggest that the use of paricalcitol, calcimimetics or the combination of both, seem to be associated with the improvement of survival in HD patients with COVID-19. No correlation was found between serum VD levels and prognosis or outcomes in HD patients with COVID-19. Prospective studies and clinical trials are needed to support these findings.

Indexed as

AgedAged, 80 and overCalcifediolCalcitriolCalciumCOVID-19Cross-Sectional StudiesErgocalciferolsFemaleHumansHyperparathyroidism, SecondaryMaleRenal DialysisRetrospective StudiesSARS-CoV-2Survival AnalysisCalcifediolCalcitriolCalciumErgocalciferolsparicalcitolVitamin DcalcifediolcalcitriolCOVID-19SARS-CoV-2survivalvitamin D

Identifiers

PMID34444716
PMCPMC8401800
OpenAlexW3186912398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.